3
|
Cardoso F, Piccart M, Rutgers E, Slaets L, van 't Veer L, Viale G, Pierga JY, Brain E, Causeret S, Golfinopoulos V, Goulioti T, Knox S, Matos E, Neijenhuis P, Nitz U, Passalacqua R, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson A, Vrijaldenhoven S, Vuylsteke P, Tryfonidis K, Bogaerts J, Delaloge S. Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-14-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- F Cardoso
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - M Piccart
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - E Rutgers
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - L Slaets
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - L van 't Veer
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - G Viale
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - J-Y Pierga
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - E Brain
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - S Causeret
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - V Golfinopoulos
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - T Goulioti
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - S Knox
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - E Matos
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - P Neijenhuis
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - U Nitz
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - R Passalacqua
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - IT Rubio
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - M Saghatchian
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - TJ Smilde
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - C Sotiriou
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - L Stork
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - C Straehle
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - G Thomas
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - A Thompson
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - S Vrijaldenhoven
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - P Vuylsteke
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - K Tryfonidis
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - J Bogaerts
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| | - S Delaloge
- Champalimaud Clinical Center/ Champalimaud Foundation, Lisbon, Portugal; Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; EORTC Headquarters, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; University of Milan&Istituto Europeao di Oncologia, Milan, Italy; Institute Curie PSL, Universite Paris Descartes, Sorbonne, Paris, France; Institute Curie- Hopital Rene Huguenin, Saint Cloud, Paris, France; Centre Georges- Francois- Leclerc, Dijon, France; Breast International Group Headquarters, Brussels, Belgium; Europpa Donna- The European Breast Cancer Coalition, Milan, Italy; Institute of Oncology, Ljubljana, Slovenia; Rijnland, Leiderdorp, Netherlands; Ev. Bethesda Kranjenhaus, Germany; Azienza Istituti Ospetalieri di Cremona, Cremona, Italy; Hospital Universitario Vall d' Hebron, Barcelona, Spain; Gustave Roussy, Villejuif, Paris, France; Jeroen Bosch Hospital, Hertogenbosch, Netherlands; Agen
| |
Collapse
|